Literature DB >> 29171814

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Johannes Oldenburg1, Gallia G Levy2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29171814     DOI： 10.1056/NEJMc1712683

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

2.  Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics.

Authors:  Donna M DiMichele
Journal:  Hemasphere       Date:  2018-10-02

Review 3.  How to discuss gene therapy for haemophilia? A patient and physician perspective.

Authors:  Wolfgang Miesbach; Brian O'Mahony; Nigel S Key; Mike Makris
Journal:  Haemophilia       Date:  2019-05-21       Impact factor: 4.287

4.  Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy.

Authors:  Johannes Schropp; Antari Khot; Dhaval K Shah; Gilbert Koch
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-01-08

Review 5.  Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.

Authors:  Sandra Le Quellec
Journal:  Drug Des Devel Ther       Date:  2020-02-03       Impact factor: 4.162

6.  Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.

Authors:  Hans H Brackmann; Wolfgang Schramm; Johannes Oldenburg; Viridiana Cano; Peter L Turecek; Claude Négrier
Journal:  Hamostaseologie       Date:  2020-07-27       Impact factor: 2.145

7.  In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.

Authors:  Jeong Pil Han; MinJeong Kim; Beom Seok Choi; Jeong Hyeon Lee; Geon Seong Lee; Michaela Jeong; Yeji Lee; Eun-Ah Kim; Hye-Kyung Oh; Nanyeong Go; Hyerim Lee; Kyu Jun Lee; Un Gi Kim; Jae Young Lee; Seokjoong Kim; Jun Chang; Hyukjin Lee; Dong Woo Song; Su Cheong Yeom
Journal:  Sci Adv       Date:  2022-01-21       Impact factor: 14.136

8.  The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study.

Authors:  Nina Haagenrud Schultz; Heidi Glosli; Stine Bjørnsen; Pål Andre Holme
Journal:  Res Pract Thromb Haemost       Date:  2021-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.